Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy - A case report

Acta Orthopaedica

Volumn 79, Issue 4, 2008, Pages 565-567

  Sayed Noor, Arkan S ^a   Sjödén, Göran O ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; BONE DENSITY CONSERVATION AGENT;

AGED; ANAMNESIS; ARTICLE; BONE RADIOGRAPHY; CASE REPORT; CLINICAL FEATURE; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; HUMAN; INTRAMEDULLARY NAILING; OSTEOPOROSIS; TREATMENT OUTCOME; BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FRACTURE HEALING; HIP FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY; TIME;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURE HEALING; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 51049122381     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/17453670710015580     Document Type: Article

References (12)

1. Black D M, Cummings S R, Karpf D B, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348 (9041): 1535-41.
2. Black D, Schwartz A, Ensrud K, Rybak-Feiglin A, Gupta J, Lombardi A, Wallace R, Levis S, Quandt S, Satterfield S, Cauley J, Cummings S. A 5 year randomized trial of the long-term efficacy and safety of alendronate. J Bone Mineral Res (Suppl 1) 2004; 10: S45 .
3. Currey J D. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 1984; 304: 509-18.
4. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
5. Goh S-K, Yang J S B, Koh M K, Wong S Y. Chua D T C, Chua T, Howe S. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg (Br) 2007; 89 (3): 49-53.
6. Kwek E B, Goh S K, Koh J S, Png M A, Howe T S. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 2008; 39 (2): 224-31.
7. Mashiba T, Turner C H, Hirano T, Forwood M R, Johnston C C, Burr D B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524-31.
8. Mashiba T, Mori S, Burr D B, Komatsubara S, Cao Y, Manabe T, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23 Suppl: 36-42.
9. Odvina C V, Zerwekh JE, Rao D S, Maalouf N, Gottschalk F A, Pak C Y C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-301.
10. Ott S. Long-term safety of bisphosphonates. Editorial. J Clin Endocrinol Metab 2005; 90: 1897-9.
11. Pauwels, F. Die Bedeutung der Bauprinzipien des Stutz- und Bewegungsapparates fur die. beanspruchung der Röhrenknochen. Anat Embryol 1948; 114: 1-2.
12. Tonino R P, Meunier P J, Emkey R, Rodriguez-Portales J A, Menkes C-J, Wasnich R D, Bone H G, Santora A C, Wu M, Desai R, Ross P D. Skeletal benefits of Aalendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000; 85: 3109-15.